Have a feature idea you'd love to see implemented?
Let us know!
XNCR Xencor Inc
Price (delayed)
$24.1
Market cap
$1.69B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.2
Enterprise value
$1.74B
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb® technology are in
Highlights
XNCR's equity is up by 28% since the previous quarter and by 8% year-on-year
The company's net income has shrunk by 67% YoY and by 12% QoQ
The EPS has shrunk by 60% YoY and by 11% QoQ
Key stats
What are the main financial stats of XNCR
Market
Valuations
Earnings
Shares outstanding
69.98M
Market cap
$1.69B
Enterprise value
$1.74B
Price to book (P/B)
2.06
Price to sales (P/S)
18.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.48
Revenue
$85.16M
EBIT
-$190.67M
EBITDA
-$178.33M
Free cash flow
$29.18M
Per share
Balance sheet
Liquidity
EPS
-$3.2
Free cash flow per share
$0.46
Book value per share
$11.71
Revenue per share
$1.33
TBVPS
$15.08
Total assets
$983.64M
Total liabilities
$262.74M
Debt
$86.59M
Equity
$723.84M
Working capital
$481.36M
Debt to equity
0.12
Current ratio
6.23
Quick ratio
6.02
Net debt/EBITDA
-0.32
Margins
Efficiency
Dividend
EBITDA margin
-209.4%
Gross margin
100%
Net margin
-232.8%
Operating margin
-255.3%
Return on assets
-21.7%
Return on equity
-30.9%
Return on invested capital
-22.2%
Return on capital employed
-21.4%
Return on sales
-223.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XNCR stock price
How has the Xencor stock price performed over time
Intraday
1.6%
1 week
2.55%
1 month
14.33%
1 year
30.27%
YTD
13.52%
QTD
19.84%
Financial performance
How have Xencor's revenue and profit performed over time
Revenue
$85.16M
Gross profit
$85.16M
Operating income
-$217.46M
Net income
-$198.24M
Gross margin
100%
Net margin
-232.8%
Xencor's net margin has shrunk by 184% YoY and by 75% QoQ
XNCR's operating margin has dropped by 151% year-on-year and by 97% since the previous quarter
The company's net income has shrunk by 67% YoY and by 12% QoQ
Xencor's operating income has decreased by 47% YoY and by 25% from the previous quarter
Growth
What is Xencor's growth rate over time
Valuation
What is Xencor stock price valuation
P/E
N/A
P/B
2.06
P/S
18.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.48
The EPS has shrunk by 60% YoY and by 11% QoQ
XNCR's equity is up by 28% since the previous quarter and by 8% year-on-year
XNCR's P/B is 24% below its 5-year quarterly average of 2.7 but 3% above its last 4 quarters average of 2.0
XNCR's P/S is 81% above its last 4 quarters average of 10.0 and 38% above its 5-year quarterly average of 13.1
XNCR's revenue is down by 41% year-on-year and by 36% since the previous quarter
Efficiency
How efficient is Xencor business performance
The ROS has shrunk by 172% YoY and by 75% QoQ
XNCR's ROE has plunged by 79% YoY and by 10% from the previous quarter
The ROA has contracted by 47% YoY and by 5% from the previous quarter
The ROIC has contracted by 36% YoY and by 4.7% from the previous quarter
Dividends
What is XNCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for XNCR.
Financial health
How did Xencor financials performed over time
XNCR's total liabilities has surged by 140% year-on-year
The company's current ratio fell by 42% YoY and by 10% QoQ
Xencor's debt is 88% lower than its equity
Xencor's debt has increased by 43% YoY
The debt to equity has increased by 33% YoY but it has decreased by 25% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.